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Abstract
Human genome sequencing is the process by which the exact order of nucleic acid base pairs in the 24 human
chromosomes is determined. Since the completion of the Human Genome Project in 2003, genomic sequencing is
rapidly becoming a major part of our translational research efforts to understand and improve human health and
disease. This article reviews the current and future directions of clinical research with respect to genomic
sequencing, a technology that is just beginning to find its way into clinical trials both nationally and worldwide.
We highlight the currently available types of genomic sequencing platforms, outline the advantages and
disadvantages of each, and compare first- and next-generation techniques with respect to capabilities, quality, and
cost. We describe the current geographical distributions and types of disease conditions in which these
technologies are used, and how next-generation sequencing is strategically being incorporated into new and
existing studies. Lastly, recent major breakthroughs and the ongoing challenges of using genomic sequencing in
clinical research are discussed.
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Introduction
Human genome sequencing, the process by which the
exact order of nucleic acid base pairs in the 24 human
chromosomes is determined, was the most significant
technical challenge of the Human Genome Project.
Completed in 2003, the 13-year project identified 20,000
to 25,000 genes and determi n e dt h es e q u e n c eo ft h e3
billion chemical base pairs that make up human DNA
as well as the regions that control them. Since then,
improvements in sequencing speed, reliability, and cost
have been the ongoing goals. Hence, genomic sequen-
cing is rapidly becoming a major part of our transla-
tional research efforts to understand and improve
human health and disease. With the numerous advances
in genomic sequencing, there has been a dramatic
increase in the number of clinical trials now using this
technology to study key disease outcomes [1].
The objective of this review is to familiarize the trans-
lational investigator with genomic sequencing technolo-
gies as they apply to clinical trials. We describe the
currently available types of genomic sequencing plat-
forms, outline the advantages and disadvantages of each,
and compare first- and next-generation techniques with
respect to capabilities, quality, and cost. To illustrate the
recent impact and widespread movement of genomic
sequencing into clinical and translational research, we
provide a summary of the types and distribution of clini-
cal studies that are using genomic sequencing to
enhance the understanding of complex pathophysiology
and identify important biomarkers of both rare and
common diseases. We provide some key examples of
clinical trials in which translational researchers are uti-
lizing this technology to better identify and individualize
the management of high-risk patients, and to achieve
major breakthroughs in drug development.
Features of First- and Next-Generation
Sequencing
So rapid are the advances in genomic sequencing tech-
nology that the methods are commonly referred to as
first- and next-generation sequencing (NGS). Sanger
sequencing, developed in the 1990s, was the earliest
method used to sequence human DNA. In fact, it was
Sanger technology that was used to sequence the
human genome in the Human Genome Project. It is
often referred to as “first-generation sequencing”
because it revolutionized how a single lab could
sequence millions (rather than thousands) of base pairs.
Sanger sequencing is a multi-channel capillary approach
that allows relatively rapid DNA sequencing. Even
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cheaper, Sanger sequencing remains in many respects
the “gold standard” for smaller validation studies, and
remains the only widely used platform that can
sequence relatively long sequences of DNA–up to 1,000
nucleotides in length (Table 1).
Several second generation sequencing technologies
have emerged over the past ten years, including Roche
454, Illumina Genome Analyzer (GA), and Applied Bio-
systems (ABI) SOLiD. These platforms are able to gen-
erate more sequence and are substantially less expensive
than the original Sanger methods (Table 1). They can
also handle more complex and smaller genomes,
sequence mRNA, copy number variants (CNV) and sin-
gle nucleotide polymorphisms (SNPs) to account for
structural variations (Table 2). In addition to whole gen-
ome sequencing, NGS technologies have been success-
fully used in chromatin immunoprecipitation (ChIP)-
sequencing to identify key binding sites of DNA-asso-
ciated proteins, [2,3] and RNA-sequencing for mamma-
lian and human tissue transcriptomes.[4-6] Due to the
cost-effectiveness and versatility of NGS as compared to
first-generation sequencing, NGS approaches are poised
to emerge as a dominant genomics technology in
patient-oriented research. Specifically, there is consider-
able interest in employing NGS platforms for targeted
sequencing of specific candidate genes and sequencing
of SNPs identified through gene-association studies.
With the declining cost of NGS technology, sequencing
of the entire human exome in large numbers of indivi-
duals is now feasible and promising [7-9].
Table 1 summarizes the advantages and disadvantages
of Sanger, Roche 454, Illumina, and SOLiD platforms
[10]. It is important to note that there is no single plat-
form that is ideal for every application, and therefore, all
four of these platforms are still widely used. With the
lower cost and more rapid turnover of the Illumina and
SOLiD platforms, the capacity for read length is limited.
Nevertheless, the rapid adoption of genome sequencing
has been fueled by rapid dropping of cost, and this may
be the main determining factor in which platforms are
used for any given clinical trial. The commercial price
of a whole genome sequencing declined from more than
$50,000 in 2009 to less than $5,000 in 2011 [7,11]. It is
anticipated that full genome sequencing will soon cost
less than $1,000 [12]. Translational investigators can
anticipate ongoing improvements in the existing tech-
nologies, and the emergence of newer approaches to off-
set cost while improving both accuracy, read length, and
turnover [13]. For example, Pacific Biosciences released
the first “third generation” sequencer this year, which
incorporates novel, single-molecule sequencing techni-
ques and advanced analytics. This system can deliver
read lengths of > 1,000 bases on average, with results
obtained in less than a day, as compared to the current
second-generation turnaround of > 1 weeks [14].
Genomics in Human Disease: Whole, Exome, and
Transcriptome Sequencing
There are currently three widely adopted approaches to
sequencing: whole genome, exome, and transcriptome
sequencing. The specific approach being used for any
Table 1 Summary of throughput, length, quality, and cost of current versions of genomic sequencing
Platform Throughput Length Quality Cost Applications Sources of error Advantages Disadvantages
Sanger 6 Mb/day 1,000 nt 10
-4-10
-5 ~
$500/
Mb
Small sample sizes, genomes,
SNPs, long haplotypes, low
complexity regions, etc.
Polymerase/
amplification, low
intensities/missing
termination variants,
contaminant sequences
Longest reads, gold
standard for
validations
High cost, low
throughput
454/
Roche
750 Mb/day 400 nt 10
-3-10
-4 ~$20/
Mb
Complex genomes, SNPs,
structural variation, indexed
samples, small RNAs, mRNAs,
etc.
Amplification, mixed
beads, intensity
thresholding,
homopolymers,
phasing, neighbor
interference
Longer reads, easier
to assemble
Medium
throughput,
expensive,
indel errors
more likely
Illumina 5,000 Mb/day 100 nt 10
-2-10
-3 ~
$0.50/
Mb
Complex genomes, counting
(SAGE, CNV Chip, small RNA),
mRNAs, structural variation,
bisulfite data, indexing SNPs,
etc.
Amplification, mixed
clusters/neighbor
interference, phasing,
base labeling
Lower cost, widely
adopted platform,
most well-
developed
bioinformatics
efforts
Higher base
substitution
error rate,
shorter reads
SOLiD 5,000 Mb/day 75 nt 10
-2-10
-3 ~
$0.50/
Mb
Complex small genomes,
counting (SAGE, ChiP, small
RNA, CNV), SNPs, mRNAs,
structural variation, indexing,
etc.
Amplification, mixed
beads, phasing, signal
decline, neighbor
interference
Lower cost, 2-base
encoding
chemistry, higher
per-base accuracy
Shortest read
lengths,
still an
emerging
platform
Adapted from Kircher, et al. Bioessays 2010
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For example, due to its significant expense, whole gen-
ome sequencing, in which the entire genome is
sequenced, is an arduous and costly methodology to
adopt. However, for collecting large amounts of DNA
sequence data from individual human subjects, the more
expensive Sanger sequencing is still widely used because
of its capacity for longer read lengths [15]. An important
limitation, however, is the extremely large sample size
required to provide adequate power for data analysis in
most whole genome studies. Therefore, more cost-effi-
cient methods are needed and the scope of these studies
is often driven by the availability of resources and fund-
ing. Whole genome and also exome sequencing (in
which only the transcribed regions of the genome are
sequenced) both attempt to find polymorphisms that
may predict drug outcome or explain mono-genic disor-
ders. At the other end of the spectrum, transcriptome
sequencing detects gene expression changes and may be
used to identify the effects of a drug on patients (phar-
macogenomics). For these types of studies, NGS is now
rapidly replacing microarray expression analysis, given
the capacity of NGS platforms to sequence more com-
plex and smaller genomes [16].
Recent whole genome studies have used NGS to gain
insight into genomic markers of disease. An excellent
example using whole genome sequencing was reported
by Mardis et al, in which 12 somatic mutations within
coding sequences and 52 somatic point mutations in
conserved regions of patients with acute myeloid leuke-
mia (AML) were identified [17]. Investigators were able
to identify two common genetic variants previously
linked with AML and two novel markers, one of which
was in a non-coding region which demonstrated regula-
tory potential. Without sequencing the entire genome,
investigators may not have understood the influence of
non-coding regions on regulatory function in AML,
highlighting a potential benefit of this approach. Other
more recent areas with promising breakthroughs using
whole-genome sequencing include: the development of
targeted chemotherapies for lung adenocarcinoma, sin-
gle-step capture and sequencing of natural DNA for the
detection of BRCA1 mutations, and the identification of
MYO1E mutations in childhood familial focal segmental
glomerulosclerosis.[18-20]
Exome sequencing has been used to gain insight and
determine genetic abnormalities in congenital defects.
This approach has been favored for a number of rea-
sons. First, this technique requires only about 5% as
much sequencing as a whole genome. In total, there are
about 180,000 exons found in the human genome. It is
estimated that the protein coding regions of the human
genome constitute about 85% of the disease-causing
mutations. A pivotal study reported in 2006 identified a
p o i n tm u t a t i o ni nF r e e m a n - S h e l d o nS y n d r o m e[ 2 1 ] .
After excluding common variants using HapMap, inves-
tigators identified the MYH3 gene mutation by sequen-
cing four individuals with the disease. Since then, exome
sequencing has been used as a popular approach to
identify rare Mendelian disorders [22-24]. These break-
throughs have led to the more widespread use of exome
sequencing to study and identify specific mutations in
Table 2 Comparison of first-, second-, and third-generation genomic sequencing
First generation Second generation Third generation
Fundamental
technology
Size-separation of specifically end-labeled
DNA fragments
Wash-and-scan SBS Single molecule real time
sequencing
Resolution Averaged across many copies of the DNA
molecule
Averaged across many copies of the DNA
molecule
Single DNA molecule
Current raw read
accuracy
High High Lower
Current read length Moderate
(800-1000 bp)
Short (generally much shorter than Sanger
sequencing)
> 1000 bp
Current throughput Low High High
Current cost High cost per base,
Low cost per run
Low cost per base,
High cost per run
Low cost per base,
High cost per run
RNA-sequencing
method
cDNA sequencing cDNA sequencing Direct RNA sequencing
Time to result Hours Days < 1 day
Sample preparation Moderately complex, PCR amplification is not
required
Complex, PCR amplification is required Various
Data analysis Routine Complex
(due to large data volumes & short reads)
Complex
Primary results Base calls with quality values Base calls with quality values Base calls with quality values
Adapted from Schadt, et al. Hum Mol Genet 2010
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[25] familial lipid disorders, [26,27] Parkinson’s Disease,
[28,29] and autism spectrum disorder [30,31].
Transcriptome sequencing encompasses experiments
including small RNA profiling and discovery, mRNA
transcript expression analysis (full-length mRNA,
expressed sequence tags and ditags, and allele-specific
expression) and the sequencing and analysis of full-
length mRNA transcripts. Transcriptome investigation
has included the areas of novel gene discovery, gene
space identification in novel genomes, assembly of full-
length genes, SNPs, and insertion-deletion and splice-
variant discovery. Transcriptome sequencing has evolved
as a robust technique for evaluating gene expression
changes from either healthy individuals who develop
disease, or within diseases themselves, such as breast
cancer and malignant metastases within the same
patient [32]. One application of this technology involved
a study of lobular breast carcinoma, in which research-
ers found 32 somatic non-synonymous coding muta-
tions present in the metastasis, and measured the
frequency of these somatic mutations in DNA from the
primary tumor of the same patient, which arose 9 years
earlier. Five of the 32 mutations (in ABCB11, HAUS3,
SLC24A4, SNX4 and PALB2)w e r ep r e v a l e n ti nt h e
DNA of the primary tumor removed at diagnosis 9
years earlier; six (in KIF1C, USP28, MYH8, MORC1,
KIAA1468 and RNASEH2A) were present at lower fre-
quencies (1-13%); 19 were not detected in the primary
tumor, and two were undetermined [33]. The combined
analysis of genome and transcriptome data revealed two
new RNA-editing events that recode the amino acid
sequence of SRP9 and COG3. Taken together, these
data show that transcriptome sequencing was useful in
identifying single nucleotide mutational heterogeneity,
which can be a property of low or intermediate grade
primary breast cancers, and that significant evolution
can occur with disease progression. Most recently,
researchers have used transcriptome sequencing
approaches to identify functional microRNA involved in
endometriosis, and diagnostic and prognostic signatures
from the small non-coding RNA transcriptome in pros-
tate cancer [34-36].
Distribution of Clinical Trials using Genomic
Sequencing
Perhaps the best resource for identifying and tracking
the growing number of studies now using genomic
sequencing is ClinicalTrials.gov [37]. This website is a
registry of federally and privately supported clinical trials
(experimental and observational) conducted in the Uni-
ted States and around the world. Since 2007, the Food
and Drug Administration mandated registration and
results reporting for clinical trials of drugs, biologics,
and devices (US Public Law 110-85). Based upon our
recent search of the website (July 2011) there were 35
registered studies in which “genomic sequencing” was
included in the protocol as either a primary or second-
ary outcome measure. Eighteen of these studies are
actively recruiting patients and six have reportedly been
completed. Figures 1 and 2 show the worldwide and U.
S. distributions of studies involving genomic sequencing
that are currently reported on ClinicalTrials.gov. The
majority of these are concentrated in the U.S. (20 stu-
dies), followed by Europe (9 studies). The highest con-
centrations of U.S. trials are based in California and
Maryland. Clusters of activity appear to be dependent
upon the types of research centers located within major
academic institutions, but this is not necessarily true for
all states.
Types of Clinical Studies
There is a wide range of studies that are now utilizing
genomic sequencing technology. The list of conditions
and diseases involved is a clear indicator of the growing
interest in understanding the role of genetic predisposi-
tion in human disease. According to ClinicalTrials.gov,
genomic sequencing technologies have been incorpo-
rated into studies on 16 categories of disease conditions.
Table 3 lists these categories and examples of associated
conditions. There is significant overlap, such that the
majority of studies fall under the three most generalized
categories involving blood/lymph, cancers/neoplasms,
and immune system diseases. The studies most repre-
sentative of the movement towards genomic sequencing
research are those involving cancer biomarker research,
including adulthood and childhood leukemias/lym-
phoma, congenital syndromes and central nervous sys-
tem disorders, HIV/AIDS research, and associated drug
developments.
According to our search, there were six recently com-
pleted clinical studies that have proposed genomic
sequencing as an outcome measure at the time of this
review. In France, an observational study of molecular
and metabolic markers in oligodendrogliomas was
recently completed with tumor collection from 189
pediatric and adult patients (NCT00213876). Research-
ers will use these tumor samples to identify diagnostic
molecular and metabolic markers that could be used as
a signature to characterize benign versus more aggres-
sive tumor histologies. Genomic sequencing and serial
analysis of genomic expression results will be correlated
to survival and clinical features of oligodendrogliomas,
medulloblastomas, and gliomas. A recently completed
epidemiological study on the distribution of insulin-like
growth factor-1 (IGF-1) deficiency in children with idio-
pathic short stature will investigate candidate genes and
DNA changes that are potentially associated with short
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scan will be further mapped at higher resolution using
DNA-sequencing (NCT00710307).
Genomic sequencing has also been incorporated as a
secondary outcome measure in a few recently completed
experimental studies: Investigators in France conducted an
open label trial to evaluate the biological effect of Tarceva
for patients with epidermoid carcinoma. A frozen tissue
bank was generated for genomic sequencing study of
tumorous epidermal growth factor receptor (EGF-R)
Figure 1 Worldwide map of clinical trials registered in ClinicalTrials.gov. Thirty-five studies were found by query of: genomic sequencing,
based upon a recent search in http://www.clinicaltrials.gov[37] (July, 2011).
Figure 2 U.S. distribution of registered clinical trials that disclose the use of genomic sequencing. In July, 2011, twenty studies reported
incorporation of NGS technology. The majority of these studies were being conducted in California (4) and Maryland (7).
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induction with the drug by RNA microarray technology
(NCT00144976). In an international phase II trial of Lapa-
tinib in patients with relapsed or refractory inflammatory
breast cancer, researchers will study tumor cell growth
and survival by quantitative immunohistochemistry and by
direct and genome-wide methods (e.g., direct sequencing
and DNA microarray) in tumor tissue collected prior to
and following 28 days of lapatinib monotherapy
(NCT00105950). In the Dominican Republic, a Phase III
randomized, double-blind, placebo-controlled study was
completed in 2008 (200 infants) to investigate horizontal
transmission of human rotavirus vaccine strain (Rotarix)
(NCT00396630). Investigators are using genomic sequen-
cing to analyze mutations in the vaccine strain after
transmission.
Thirteen of the 35 studies were designed with geno-
mic sequencing results as a primary outcome measure
(Table 4). The most recently registered trial by the
Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD) will allow
for exomic sequencing of participating NICHD patients
and their family members. Included in this study are
probands that are enrolled in an NICHD clinical
protocol for which there is a suspicion of an underlying
genetic cause for a disease for which they are being eval-
uated. Many other studies are capitalizing on up-and-
coming NGS technology, including feasibility and pilot
studies of solid tumors and leukemias, and whole gen-
ome sequencing studies for a wide array of congenital
disorders, cardiovascular diseases, hematologic condi-
tions and endocrine disorders. What is common in the
diseases being studied is the potential for improved out-
come with earlier diagnosis and treatment. Hence, trans-
lational researchers are recognizing the potential of
genomic sequencing technology as an important diag-
nostic and screening tool in the clinical setting.
Largest U.S. Patient Samples
There are a few large-scale epidemiological studies that
have begun to incorporate genomic sequencing as a major
part of their observations. For example, the largest U.S.
sample registered at the time of this review, sponsored by
the National Cancer Institute (NCI), has enrolled 3,000
patients to study gene expression of lymphoma, leukemia,
and multiple myeloma (NCT00339963). In this trial, DNA
sequencing methods are being used to analyze base
changes in the genome of the cancer cells. While there are
Table 3 Condition categories and diseases studied utilizing genomic sequencing technology.
Condition Diseases
Bacterial and Fungal Diseases Mycoses, Osteitis, Pelvic Infection, Pelvic Inflammatory Disease, Proteus Infections
Blood and Lymph Conditions Anemia, Blood Coagulation, Burkitt Lymphoma, Hodgkin Disease, Hemorrhagic, Hemoglobinopathies, Leukemias,
Lymphomas, Lymphoproliferative Disorders, Multiple Myeloma
Cancers and Other Neoplasms Adenocarcinoma, Neuroblastoma, Nevus, Osteosarcoma, Retinoblastoma, multiple neoplasms, carcinomas, etc.
Digestive System Diseases Digestive System Neoplasms, Duodenal Diseases, Gastroenteritis, Ileal, Jejunal, Stomach Diseases and Neoplasms
Diseases and Abnormalities at or
before Birth
Multiple congenital anomalies, Cardiovascular Anomalies/Congenital Heart Disease, Inborn Diseases,
Hemoglobinopathies, Neurocutaneous Syndromes, Neurofibromatoses
Ear, Nose, and Throat Diseases Deafness, Hearing Disorders, Hearing Loss
Eye Diseases Retinoblastoma
Gland and Hormone Related
Diseases
Acromegaly, Endocrine Disorders, Dwarfism, Neoplasms, Hyperparathyroidism, Parathyroid and Pituitary Diseases
Heart and Blood Diseases Aortic Valve Stenosis, Arterial Occlusive Diseases, Cardiomyopathies, Coronary Artery Disease, MI
Immune System Diseases AIDS, Lymphomas, Hodgkin Disease, Immunoproliferative Disorders, Leukemias, Myelomas, Mycosis,
Macroglobulinemia
Muscle, Bone, and Cartilage
Diseases
Acromegaly, Bone Diseases, Dwarfism, Congenital Limb Anomalies, Musculoskeletal Abnormalities, Osteitis
Nervous System Diseases ALS, Aphasias, Brain Neoplasms, CNS Diseases, Coma, Communication Disorders, Deafness, Dementia/Delirium,
Motor Neuron Diseases, Neurocutaneous Syndromes, Neurodegenerative Diseases, Neurofibromas/NF,
Neuromuscular Diseases, Pain, Speech Disorders, Spinal Cord Diseases
Skin and Connective Tissue
Diseases
Breast Diseases/Neoplasms, Neurocutaneous Syndromes
Symptoms and General Pathology Coma, Communication, Deafness/Delirium, Hearing Disorders, Hemolysis, Inflammation, Ischemia,
Neurobehavioral, Pain, Sclerosis, Sepsis/Shock
Urinary Tract, Sexual Organs, &
Pregnancy
Adnexal Diseases, Renal Cell Carcinoma, Endometritis, Kidney Diseases, Pelvic Inflammatory Disease, Prostatic
Neoplasms, Urogenital Neoplasms, Uterine and Urologic Diseases, Wilm’s Tumor
Viral Diseases AIDS, Burkitt Lymphoma, HIV Infections
Source: http://www.clinicaltrials.gov (July, 2011)
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whole genomes from a few patients, the much larger num-
ber of cases in this trial will allow researchers to identify
biologically relevant patterns in humans [33,38-41]. The
National Human Genome Research Institute (NHGRI) has
enrolled 2,000 patients to examine genomic sequencing in
clinical research on coronary artery disease (ClinSeq,
NCT00410241). Researchers will start by sequencing
about 400 genes related to heart disease, with the eventual
goal of sequencing most or all of participants’ genes. The
National Institute of Allergy and Infectious Disease
(NIAID) has enrolled 1,200 patients to develop diagnostic
tests for community acquired pneumonia (CAP) and sep-
tic shock (NCT00258869). In this study, advanced bioin-
formatic, metabolomic, and proteomic approaches will be
used with mRNA sequencing to identify protein changes
in blood samples that predict outcomes in sepsis and CAP.
Ethical and Computational Challenges in
Translational Medicine
As the cost of NGS technology is becoming less of a
limitation, several inherent challenges remain that must
Table 4 Active and completed studies using genomic sequencing results as the primary outcome measure (source:
http://www.clinicaltrials.gov, July 2011)
Study Title/Sponsor NCT #/
# Enrolled/
Start Date
Condition Description
Next Generation to Identify Genetic Causes of
Disease in Patients Participating in NICHD Clinical
Protocols
NICHD
NCT01375543
100
June 2011
Genetic diseases
(pediatric)
Use of DNA samples to conduct exome and genome
sequencing
Feasibility Clinical Study of Targeted and Genome-
Wide Sequencing
University Health Network, Toronto
NCT01345513
100
March 2011
Solid Tumors Targeted and genome-wide sequencing of DNA to enable
molecular characterization of tumors.
Biomarkers in Tissue Samples from Patients with
High-Risk Wilms Tumor
NCI
NCT01118078
100
March 2010
Kidney Cancer Application of array-based methods and NGS to identify
candidate molecular targets
Whole Genome Medical Sequencing for Genome
Discovery
NHGRI
NCT01087320
100
Feb 2010
Congenital
Syndromes/
Genetic
Disorders
Using genomic sequencing to identify genetic causes of
disorders that are difficult to identify with existing
techniques
Studying DNA in Tumor Tissue Samples from
Patients with Localized or Metastatic Osteosarcoma
NCI
NCT01062438
99
Jan 2010
Sarcoma Genomic expression profile in osteosarcoma tumor samples
using transcriptome sequencing
Genetics of Congenital Heart Disease
Nationwide Children’s Hospital
NCT01192048
1000
Dec 2009
Congenital Heart
Disease
Direct sequencing and/or microarray, whole-genome array
comparative genomic hybridization (CGH)
Integrated Whole-Genome Analysis of Hematologic
Disorders
Stanford University
NCT01108159
100
Sept 2009
Hematologic
Diseases
Whole-genome analysis/high-throughput sequencing using
blood, bone marrow and skin biopsy samples
Study of Tissue Samples from Patients with
Lymphoma
NCI
NCT00952809
300
March 2009
Lymphoma;
Small Intestinal
Cancer
Generation of genome-wide maps of the distribution of
nucleosomes and histone modifications as assessed by high
throughput sequencing (ChIP-Seq)
Genetics of Endocrine Tumours
Barts & The London NHS Trust
NCT00461188
150
March 2007
Acromegaly Tumor samples studied using candidate gene sequencing
DNA Analysis of Tumor Tissue Samples from
Patients with Diffuse Brain Stem Glioma
St. Jude Children’s Research Hospital
NCT00899834
30
June 2006
Brain & CNS
Tumors
Genome-wide expression of RNA in tumor samples using
gene expression profiling. Direct sequencing analysis of
tumor DNA
ClinSeq: A Large-Scale Medical Sequencing Clinical
Research Pilot Study
NHGRI
NCT00410241
2000
Dec 2006
Cardiovascular
Disease
Sequencing ~ 400 genes related to heart disease
Laboratory Study of Lymphoblasts in Young
Patients with High-Risk ALL
NCI
NCT00896766
150
July 2006
Leukemia Pilot application of array-based methods and gene re-
sequencing to identify candidate molecular targets for ALL
Genome Expression in Lymphoma, Leukemia and
Multiple Myeloma
NCI
NCT00339963
3000
Nov 2001
Lymphoma,
Leukemia
Multiple
Myeloma
Participating centers send samples to the NCI for gene
expression profiling, array-based comparative genomic
hybridization and cancer gene re-sequencing.
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tional investigator are the ethical, legal and social issues
surrounding genomic sequencing. In a recent study con-
ducted by Allen and Foulkes, 30 cancer genome sequen-
cing studies were assessed to evaluate how these issues
are being handled across different jurisdictions [42].
W h i l et h e yf o u n dah i g hd e g r e eo fs i m i l a r i t yi nh o w
cancer researchers engaged in these studies were pro-
tecting participant privacy, there were no consistent
m e a n sa c r o s st h e s es t u d i e sf o rr e - c o n t a c t i n gp a r t i c i -
pants, or for returning results and facilitating participant
withdrawal. There was a strong trend towards both
using samples for additional, unspecified research and
sharing data with other investigators. Given the unique
nature of genomic sequencing research, individuals and
groups engaging in NGS clinical trials may benefit from
human subjects training in these specific areas. How-
ever, it is apparent that better-defined consensus stan-
dards are still needed both nationally and internationally
to prepare the growing number of researchers in this
field [43,44].
With the vast amounts of high-quality, complex data
now being processed through NGS, an ongoing challenge
for translational researchers remains: How do we deal
with the computational complexities of analyzing this
data? NGS can miss parts of the genome that may be clini-
cally important. It detects mainly small polymorphisms,
though it could be used to detect larger copy number var-
iations. Multiple comparison and sample size issues
remain an ongoing problem. In general, the computational
complexities of properly handling genomic sequencing
data have lagged behind the development of the technol-
ogy. Such challenges may only be addressed through the
development of innovative bioinformatic approaches, and
through strategic collaboration and knowledgeable study
design and implementation by translational investigators.
Computerized technological advances are rapidly becom-
ing in high demand [45]. Two promising areas that are
being used to bridge the gap between genomics and the
bedside are the development of biologically and medically
focused text mining algorithms and the integration of the
electronic medical record (EMR). Both may speed the pro-
cess of collection and analysis of structured data. However,
these methods require further development and ongoing
validation, especially before applying the information in
the clinical setting.
Conclusion
In summary, rapid advances in genomic sequencing
have paved the way for the incorporation of NGS into
clinical applications. With NGS technology there is
much improved cost-effectiveness and more rapid turn-
over, two critical success factors that are highly appeal-
ing to clinical and translational investigators. In the
past, studies that implement gene sequencing have been
concentrated around major academic institutions, but
this is not expected to continue in the future. With
more readily available and cost-effective markets now
capitalizing on complete human genome sequencing
and analysis as an outsourced service, the use of this
technology is likely to become more automated, with
significant impact on national and international econo-
mies [46]. As illustrated in this review, there is an
increasing use of genomic sequencing in the U.S. and
worldwide, with a wide range of disease conditions now
studied that may soon replace microarray approaches in
the new era of bioinformatics. Since these technological
approaches are highly applicable for both rare Mende-
lian and well as more complex and common diseases,
the future of genomics is promising.
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